{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:10:32Z","timestamp":1790327432317,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AR072583"],"award-info":[{"award-number":["P30AR072583"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The opportunity for new biomarker\u2010based tests to predict treatment response and the appropriate use of emerging rheumatoid arthritis (RA) therapies may depend on patients\u2019 treatment history. We examined RA treatment sequences and biologic\/JAK inhibitor (JAKi) initiation overall and by line of therapy (LoT) to estimate the size of the eligible RA patient population in the United States for a new predictive treatment response test using a population\u2010based RA inception cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used an augmented health plan claims database to create an inception cohort of patients with RA and estimated the rate of advanced treatment (biologic or JAKi) addition or switch. Results were stratified by advanced treatment\u2013na\u00efve versus treatment\u2010experienced status and also described specific RA treatment sequences and combinations over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 37,656 patients with RA, 59,557 new RA treatment initiations were identified. Most patients (85.2%) initiated biologics; the remainder initiated JAKi. Of these, 40.2% used biologics\/JAKi as monotherapy. The overall biologic\/JAKi addition\/switch rate was 25.7 per 100 patient\u2010years (py) (22.7\/100 py in biologic\u2010na\u00efve patients and &gt;30\/100 py in treatment\u2010experienced patients). Rates varied substantially between prescribers, with an observed add\/switch rate in the practices of prescribers in the highest decile (53.8\/100 py) more than four\u2010fold greater than rates in the practice of prescribers in the lowest decile (12.1\/100 py).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings highlight the size and characteristics of the eligible RA population in the United States initiating a new RA biologic or JAKi treatment each year, thus providing valuable insights for stakeholders developing or marketing new RA therapies or biomarker\u2010based diagnostic tests to predict future treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.80025","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:42:47Z","timestamp":1771238567000},"page":"1387-1396","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Sequencing and Line of Therapy for Biologics and\n                    <scp>JAK<\/scp>\n                    Inhibitors in Patients With Rheumatoid Arthritis: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R.","family":"Curtis","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham  Birmingham Alabama"},{"name":"Foundation for Advancing Science, Technology, Education, and Research  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanette","family":"Daigle","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education, and Research  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1811-6602","authenticated-orcid":false,"given":"Emily E.","family":"Holladay","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Su","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education, and Research  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-2308","authenticated-orcid":false,"given":"Michael","family":"George","sequence":"additional","affiliation":[{"name":"University of Pennsylvania  Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Lam","sequence":"additional","affiliation":[{"name":"Arthritis and Osteoporosis Consultants of the Carolinas\/Atrium Health Wake Forest Baptist  Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Levin","sequence":"additional","affiliation":[{"name":"Clinical Research of West Florida, Inc  Clearwater"},{"name":"University of South Florida  Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Reddy","sequence":"additional","affiliation":[{"name":"Southwest Florida Rheumatology  Riverview"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglong","family":"Xie","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education, and Research  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Mudano","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education, and Research  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11081362"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755844"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06806-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001945"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00168-5"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2076-7"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0759-0"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/nsm.2020.0007"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70067"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3506-3"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa393"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.075"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02310-z"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_7_18_1","unstructured":"Pfizer.Pfizer shares co\u2010primary endpoint results from post\u2010marketing required safety study of XELJANZ\u00ae (tofacitinib) in subjects with rheumatoid arthritis (RA). Pfizer Inc.https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-co-primary-endpoint-results-post-marketing"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200367"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041291"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3726-1"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.146365"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23533"},{"issue":"9","key":"e_1_2_7_24_1","article-title":"Line of therapy of biologics and JAK inhibitors in RA, PsA and AxSpA: implications for design and uptake of new drugs and diagnostics [abstract]","volume":"75","author":"Curtis J","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25269"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.80025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:38:43Z","timestamp":1790325523000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.80025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/acr.80025"],"URL":"https:\/\/doi.org\/10.1002\/acr.80025","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"2025-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}